
Opinion|Videos|January 31, 2025
Handling Dose Modifications and Treatment Interruptions Due to AEs With Bispecifics
Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due to adverse events (AEs), including experiences where these adjustments significantly impacted patient outcomes.
Advertisement
Video content above is prompted by the following:
- How do you handle dose modifications or treatment interruptions due to AEs?
- Can you share any experiences where such modifications significantly impacted patient outcomes?
Advertisement
Related to this article

As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.

A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.

Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.

Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.

Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.

At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.

Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
2
Childhood Leukemia Treatment Disrupts Work, Finances for Most Families
3
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
4
What Nurses Should Tell Patients About Vitamin C in CCUS and MDS
5

